EUVIMEDEUVIMED entdecken
Crossref

Rational design of Gi-biased CB1 agonist with reduced side effects

Yu-Ying Liao, Jinxin Che, Yun-Tao Gao, Jianheng Xue, Linjie Li, Lin-Lin Wu, Jia-Xue Hu, Meng-Ting Hu, Linghua Xie, Huibing Zhang, Dan-Dan Shen, Yingjun Dong und 6 weitere

Cell · 2026-05 · 189 (11) · 3432-3443.e16

DOI: 10.1016/j.cell.2026.03.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2026-05. Verfasst von Yu-Ying Liao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Department of Psychiatry of Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China; N…. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB1, Drug Design, Cannabinoid Receptor Agonists, GTP-Binding Protein alpha Subunits, Gi-Go. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: Zhejiang Province Natural Science Foundation, National Major Science and Technology Projects of China, Ministry of Science and Technology of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cannabinoid receptor 1 (CB1) has emerged as a promising candidate for next-generation non-opioid therapies. However, the development of therapeutics targeting CB1 has been consistently hindered by significant adverse effects. Here, through structure-activity relationship analyses focused on biased signaling, we rationally design two Gi-biased CB1 agonists, LZD503 and LZD505. Our design strategy employed structural spatial tuning of the agonist scaffold to disrupt specific molecular interactions and minimize steric conflicts with critical tip residues within the ligand-binding pocket, thereby promoting preferential Gi-pathway signaling. Cryo-electron microscopy structures of the CB1-G-protein complexes bound to these designed agonists confirmed that their anticipated conformational poses favored Gi-biased signaling. Both designed compounds demonstrated promising results by alleviating pain and mitigating unwanted responses in mice. The elucidated CB1 complex structures and the resulting insights establish a comprehensive framework for the structure-guided development of innovative CB1-targeted analgesics with reduced adverse effect profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Cannabinoid, CB1Drug DesignCannabinoid Receptor AgonistsGTP-Binding Protein alpha Subunits, Gi-GoAnimalsHumansMiceStructure-Activity RelationshipCryoelectron MicroscopySignal TransductionHEK293 CellsAnalgesics

Stichwörter der Autor:innen

CB1analgesiccannabinoidnon-opioidrational designsignaling bias

Substanzen

Receptor, Cannabinoid, CB1Cannabinoid Receptor AgonistsAnalgesicsGTP-Binding Protein alpha Subunits, Gi-Go

Autor:innen und Institutionen

  • Department of Neurology and Department of Psychiatry of Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China; Nanhu Brain-Computer Interface Institute, Hangzhou 311100, China; NHC a…
  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Department of Pathology of Sir Run Run Shaw Hospital, Department of Pharmacology and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Department of Neurology and Department of Psychiatry of Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China; Institute of Pharmacology and Toxicology, College of Pharmaceutical Sci…
  • NHC and CAMS Key Laboratory of Medical Neurobiology, MOE Frontier Center of Brain Science and Brain-Machine Integration, School of Brain Science and Brain Medicine, Liangzhu Laboratory, Zhejiang University, Hangzhou 310…
  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: dongxw@zju.edu.cn.

Förderung

  • Zhejiang Province Natural Science Foundation
  • National Major Science and Technology Projects of China
  • Ministry of Science and Technology of the People's Republic of China
  • National Key Research and Development Program of China Stem Cell and Translational Research
  • Chinese Academy of Sciences
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Liao, Y. Y., Che, J., Gao, Y. T., Xue, J., Li, L., Wu, L. L., Hu, J. X., Hu, M. T., Xie, L., Zhang, H., Shen, D. D., Dong, Y., Zang, S., Zhang, N., Wang, H., Zhang, Y., Dong, X., & Li, X. M. (2026). Rational design of Gi-biased CB1 agonist with reduced side effects. Cell, 189(11), 3432-3443.e16. https://doi.org/10.1016/j.cell.2026.03.020

Vancouver

Liao YY, Che J, Gao YT, Xue J, Li L, Wu LL, et al. Rational design of Gi-biased CB1 agonist with reduced side effects. Cell. 2026;189(11):3432-3443.e16. doi:10.1016/j.cell.2026.03.020

BibTeX
@article{Liao2026,
  author = {Liao, Yu-Ying and Che, Jinxin and Gao, Yun-Tao and Xue, Jianheng and Li, Linjie and Wu, Lin-Lin and Hu, Jia-Xue and Hu, Meng-Ting and Xie, Linghua and Zhang, Huibing and Shen, Dan-Dan and Dong, Yingjun and Zang, Shaokun and Zhang, Na and Wang, Hao and Zhang, Yan and Dong, Xiaowu and Li, Xiao-Ming},
  title = {Rational design of Gi-biased CB1 agonist with reduced side effects},
  journal = {Cell},
  year = {2026},
  volume = {189},
  number = {11},
  pages = {3432--3443.e16},
  doi = {10.1016/j.cell.2026.03.020}
}
Kostenlos starten →